Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

Semaglutide may relieve peripheral arterial disease experienced by many patients with type 2 diabetes, a new Montreal study suggests. Peripheral arterial disease is a difficult-to-treat problem ...

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

The annual meeting of the American College of Cardiology was held from March 29 to 31 in Chicago and attracted more than ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes.